CIPLA Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CIPLA, and what generic alternatives to CIPLA drugs are available?
CIPLA has ninety-two approved drugs.
There are six US patents protecting CIPLA drugs. There are thirty-three tentative approvals on CIPLA drugs.
There are thirty patent family members on CIPLA drugs in twenty-one countries and four hundred and thirty-nine supplementary protection certificates in seventeen countries.
Summary for CIPLA
| International Patents: | 30 |
| US Patents: | 6 |
| Tradenames: | 81 |
| Ingredients: | 81 |
| NDAs: | 92 |
| Patent Litigation for CIPLA: | See patent lawsuits for CIPLA |
| PTAB Cases with CIPLA as petitioner: | See PTAB cases with CIPLA as petitioner |
Drugs and US Patents for CIPLA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cipla | PHYTONADIONE | phytonadione | INJECTABLE;INJECTION | 212424-001 | Apr 22, 2022 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Cipla | PRAVASTATIN SODIUM | pravastatin sodium | TABLET;ORAL | 077904-003 | Oct 23, 2006 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Cipla | DARUNAVIR | darunavir | TABLET;ORAL | 206288-001 | Nov 28, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Cipla Ltd | ZIDOVUDINE | zidovudine | CAPSULE;ORAL | 078349-001 | May 23, 2007 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for CIPLA Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Lithuania | 2217610 | ⤷ Try a Trial |
| Japan | 5624766 | ⤷ Try a Trial |
| Spain | 2613936 | ⤷ Try a Trial |
| South Korea | 20100110297 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for CIPLA Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1131065 | 1490039-3 | Sweden | ⤷ Try a Trial | PRODUCT NAME: DIMETHYL FUMARATE; REG. NO/DATE: EU/1/13/837 20140130 |
| 1746976 | CA 2017 00030 | Denmark | ⤷ Try a Trial | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL)...; REG. NO/DATE: EU/1 /16/1130 20161018 |
| 1419152 | C 2012 016 | Romania | ⤷ Try a Trial | PRODUCT NAME: COMBINATIE DE RILPIVIRINA SI TOATE FORMELE ECHIVALENTETERAPEUTIC ALE ACESTEIA CUM AR FI SARURILE DE ADITIE ALE RILPIVIRINEI ACCEPTABILE FARMACEUTIC, INCLUSIV SAREARILPIVIRINEI CU ACIDUL CLORHIDRIC, SI TENOFOVIR, IN PARTICULAR FUMARAT DE TENOFOVIRDISOPROXIL; NATIONAL AUTHORISATION NUMBER: EU/1/11/737/001, EU/1/11/737/002; DATE OF NATIONAL AUTHORISATION: 20111128; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/737/001, EU/1/11/737/002; DATE OF FIRST AUTHORISATION IN EEA: 20111128 |
| 1663240 | 93382 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: COMBINAISON DE RILPIVIRINE OU UNE FORME THERAPEUTIQUE EQUIVALENTE QUI EN DERIVE TELLE QUE PROTEGEE PAR LE BREVET DE BASE, TEL QU'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE RILPIVIRINE, INCLUANT LE SEL CHLORHYDRATE DE RILPIVIRINE ET TENOFOVIR ALAFENAMIDE, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE FUMARATE DE TENOFOVIR ALAFENAMIDE; AUTHORISATION NUMBER AND DATE: EU/1/16/1112 ODEFSEY - EMTRICITABINE |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
